Athenex, Inc.
24
0
0
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
4 terminated/withdrawn out of 24 trials
80.0%
-6.5% vs industry average
13%
3 trials in Phase 3/4
25%
4 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
Role: lead
A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Role: lead
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Role: lead
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Role: lead
Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer
Role: lead
Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
Role: lead
Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer
Role: lead
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Role: lead
An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
Role: lead
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
Role: lead
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
Role: lead
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
Role: lead
A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
Role: lead
A Phase I Open-label Study for Subjects With Advanced Malignancies
Role: lead
A PK Study of Oraxol in Breast Cancer Patients
Role: lead
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
Role: lead
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
Role: collaborator
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
Role: collaborator
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
Role: collaborator
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
Role: lead